Introduction
============

Vasopressor therapy is current practice for treatment of arterial hypotension associated with septic shock, but may result in gut dysfunction due to intestinal vasoconstriction. Therefore we compared the effects of vasopressor treatment with the nitric oxide synthase inhibitor L-NMMA with those of noradrenaline (NOR) on intestinal O~2~ transport as well as energy balance in a porcine hyperdynamic endotoxic shock model.

Methods
=======

Thirty anesthetized pigs were studied; 12 h after induction of endotoxic shock with continuous LPS infusion animals were randomly assigned to receive either no drug therapy (ETX, *n* = 8), or vasopressor support with noradrenaline (NOR, *n* = 11) or L-NMMA (L-NMMA, *n* = 11), respectively, in order to maintain MAP at preshock levels. Portal venous blood flow (Transonic flow probes), arterial-portal venous O~2~ extraction, ileal mucosal intracapillary HbO~2~ saturation (remission spectrophotometry EMPHO) and arterial-ileal mucosal PCO~2~ gaps were measured.

Results
=======

Data are median and interquartile range. \**P* \< 0.05 vs preshock (RM ANOVA on ranks). (See table overleaf.)

Conclusions
===========

Despite well-preserved O~2~ availability neither of the two treatments could reverse the endotoxin induced derangement of intestinal energy balance.

                                     Preshock              12 h                 18 h                 24 h
  --------------------- ------------ --------------------- -------------------- -------------------- --------------------
  Portal venous         ETX          23 (19;28)            25 (29;28)           24 (20;29)           28 (19;31)
  blood flow            NOR^\*^      23 (20;26)            25 (18;28)           36 (26;37)           38 (28;42)
  (ml/min/kg)           L-NMMA       24 (22;28)            32 (24;40)           26 (23;36)           30 (19;34)
  O~2~ extraction       ETX          34 (27;35)            29 (20;33)           26 (23;32)           26 (25;35)
  (%)                   NOR^\*^      32 (26;35)            31 (27;41)           20 (18;24)           22 (1 7;32)
                        L-NMMA       31 (29;34)            31 (27;35)           31 (27;31)           31 (24;54)
  ileal mucosal         ETX          43 ± 13               39 ± 21              37 ± 10              30 ± 10
  intracap. HbO~2~      NOR          46 ± 15               44 ± 12              44 ± 8               45 ± 14
  Mean ± SD             L-NMMA       48 ± 12               43 ± 11              42 ± 11              42 ± 12
  Portal venous         ETX^\*^      25.1 \[22.0;29.1\]    25.3 \[22.5;28.5\]   31.8 \[22.8;34.7\]   42.7 \[40.0;54.5\]
  Lac/Pyr ratio         NOR^\*^      28.1 \[26.1 ;31.3\]   31.3 \[24.8;37.6\]   46.4 \[39.0;53.3\]   44.7 \[36.6;65.9\]
                        L-NMMA^\*^   20.8 \[18.6;29.5\]    26.5 \[25.3;40.4\]   39.9 \[28.4;50.5\]   48.0 \[44.3;53.2\]
  ileal mucosal-        ETX^\*^      12 (9;13)             13 (11;20)           17 (14;25)           20 (19;28)
  arterial PCO~2~ gap   NOR^\*^      13 (4;15)             19 (16;29)           19 (13;26)           15 (11;53)
  (mmHg)                L-NMMA^\*^   13 (11;16)            23 (17;29)           37 (13;53)           44 (28; 45)
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